Is the Sinovac vaccine effective for children aged 3 to 17? Notice for Sinovac vaccine recipients

At present, Beijing Kexing Zhongwei Xinguan inactivated vaccine has been approved, and the age range of use has been extended to more than 3 years old, which means that minors aged 3 to 17 can be vaccinated with Beijing Kexing vaccine. Is it good to receive the Sinovac vaccine between the ages of 3 and 17? Is it good to receive the Sinovac vaccine between the ages of 3 and 17? After receiving the vaccine between the ages of 3 and 17, its safety is good, which is the same as that of the 18-year-old adult group. At the same time, the antibody levels are the same as in adults. The clinical research of children group (3 to 17 years old) has been in the sequence of clinical trials of Sinovac COVID-19 vaccine. Sinovac Biotech started Phase I and Phase II clinical trials at the beginning of this year, and the clinical trial data was unblinded on March 12th. The analysis results showed that within 28 days after the second dose of vaccination, the incidence of vaccine related adverse events (adverse reactions) in the low-dose group, medium dose group, and placebo group was 2

5.57%, 29.03%, and 2

3.68%, respectively, with no statistically significant difference in incidence between groups. Adverse reactions are mainly mild and moderate, with pain at the vaccination site being the main symptom. Other symptoms did not show a trend of higher incidence in the vaccine group than in the placebo group, and the incidence of fever in each group was only 4.11% -5.07%. No serious adverse events related to vaccines have occurred. 28 days after receiving two doses of the vaccine, the neutralizing antibody conversion rates in the low-dose and medium dose groups were 9

6.77% and 100%, respectively, with GMTs of 86.4 and 14

2.2. Therefore, children and adolescents aged 3-17 years old who received two doses of Kexing Zhongwei COVID-19 vaccine every 28 days have good safety and immunogenicity, and the antibody level is significantly higher than that of adults and the elderly, suggesting that COVID-19 vaccine may have better protection effect on minors than adults and the elderly. According to the official WeChat official account of China Biotech, which COVID-19 vaccines can be taken at the age of 3 to 17, the COVID-19 inactivated vaccine of Sinopharm China Biotech Beijing Institute of Biological Products was approved for emergency use among people aged 3-17 after the relevant departments of the joint prevention and control mechanism of the State Council organized the demonstration. China COVID-19 inactivated vaccine was officially approved for emergency use in this age group. At present, Sinopharm China Bio COVID-19 Vaccine has completed Phase I/II clinical trials in Henan Province for the 3-17 age group. The positive conversion rate of neutralizing antibodies in the 3-17-year-old population after immunization is 100%, and there is no significant difference in neutralizing antibody GMT and positive conversion rate compared to the adult group.